[Pharmacological and clinical profiles of miglustat (Brazaves(®)) for the treatment of Niemann-Pick type C disease]

Nihon Yakurigaku Zasshi. 2013 Mar;141(3):160-7. doi: 10.1254/fpj.141.160.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 1-Deoxynojirimycin / analogs & derivatives*
  • 1-Deoxynojirimycin / pharmacology
  • 1-Deoxynojirimycin / therapeutic use
  • Animals
  • Calcium / metabolism
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology*
  • Enzyme Inhibitors / therapeutic use*
  • Glucosyltransferases / antagonists & inhibitors
  • Humans
  • Lysosomes / metabolism
  • Mice
  • Niemann-Pick Disease, Type C / drug therapy*
  • Niemann-Pick Disease, Type C / physiopathology

Substances

  • Enzyme Inhibitors
  • 1-Deoxynojirimycin
  • miglustat
  • Glucosyltransferases
  • ceramide glucosyltransferase
  • Calcium